Global Oral Solid Dosage Contract Manufacturing Market Set for Continued Growth Through 2028

Dublin, April 02, 2024 (GLOBE NEWSWIRE) -- The "Oral Solid dosage (OSD) Contract Manufacturing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F" report has been added to's offering.

Market Overview

The Global Oral Solid Dosage (OSD) Contract Manufacturing Market is witnessing a significant upsurge, with projections indicating a robust Compound Annual Growth Rate (CAGR) of 6.24% from 2023 to 2028. 2022 saw the market valuation at a commendable USD 33.45 billion, spurred by the rising demand for solid dosage forms such as tablets, capsules, powders, and granules. In line with this growth trajectory, the industry is expected to see an influx of innovation, strategic collaborations, and an expansion of services offered by Contract Manufacturing Organizations (CMOs) to pharmaceutical companies on a worldwide scale.

Driving Forces Behind the Market Expansion

A plethora of factors contribute to the thriving nature of the OSD Contract Manufacturing Market, including but not limited to cost efficiency, focus on core competencies, rising drug development, and groundbreaking technological advancements. Cost efficiency emerges as a prime motivator, as pharmaceutical firms seek to harness the specialized infrastructures of CMOs to optimize production costs. Concurrently, the shift to focus on core competencies such as R&D and marketing allows pharmaceutical entities to propel innovation while contract manufacturers handle production intricacies. The ever-increasing pipeline of drug development and the integration of advanced technological systems in manufacturing processes further catalyze market growth, thereby enhancing both efficiency and product quality.

Challenges to Navigate

Despite the positive outlook, the market faces certain challenges like rigorous quality control and assurance protocols, as well as the need to meticulously navigate intellectual property issues. QC and QA play a critical role in meeting regulatory requirements and maintaining product integrity, while safeguarding IP is essential to preserve proprietary formulations and technologies during collaborations between pharmaceutical companies and CMOs.

Emerging Trends Shaping the Future

The market is also observing progressive trends such as an increased focus on biopharmaceuticals and complex formulations. OSD contract manufacturers are advancing their techniques to accommodate the production needs of these sophisticated drug forms. Additionally, the emphasis on sustainability and green manufacturing practices is increasing as companies seek to reduce environmental impact and engage in more resource-efficient production methodologies. As per product insights, the market for tablets holds a predominant share and is expected to maintain its lead, attributing to their widespread acceptance as the most conventional form of oral solid dosage. On the regional front, North America continues to spearhead the market, positioned for further expansion, driven by an increase in chronic disease prevalence and advancements in healthcare infrastructure.

Segmental Insights and Competitive Landscape

The market is analyzed across a range of segments, including product types such as capsules, powders, granules, and others. Moreover, the end-user base spans large-size companies, small and medium-size companies, as well as startups and generic pharmaceutical firms. Geographic analysis covers North America, Europe, Asia-Pacific, South America, and the Middle East & Africa, providing a comprehensive global perspective. The competitive landscape is typified by major players who influence the Global Oral Solid Dosage Contract Manufacturing market, each contributing to the industry's evolution with their strategic initiatives. As this market segment matures, the synergies formed between pharmaceutical companies and OSD CMOs will play a crucial role in shaping the future of drug manufacturing and delivery.

As adherence to stringent quality standards and regulatory requirements continues, and with the increasing drive towards technological innovations, the OSD Contract Manufacturing Market is poised for sustained growth in the upcoming years. The industry's adaptation to the evolving demands of pharmaceutical development signals an era of unprecedented opportunities and collaborative advancements.

Key Attributes

Report AttributeDetails
No. of Pages178
Forecast Period2023 - 2028
Estimated Market Value (USD) in 2023$33.45 Billion
Forecasted Market Value (USD) by 2028$47.75 Billion
Compound Annual Growth Rate6.2%
Regions CoveredGlobal

A selection of companies mentioned in this report includes, but is not limited to:

  • AbbVie Inc.
  • Acino International AG
  • Aenova Holding GmbH
  • Beximco Pharmaceuticals Ltd
  • Boehringer Ingelheim International GmbH
  • Catalent Inc.
  • Corden Pharma International GmbH,
  • PerkinElmer Inc.
  • Pyramid Laboratories Inc.
  • Siegfried AG.

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.


Global Oral Solid dosage (OSD) Contract Manufacturing Market

Contact Data